Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.57 |
| ▸ | BCL9 | O00512 | 1/20 | 0.55 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8372727 | 1.00 | MGLL (0.57) | MGLLBCL9CTNNB1HDAC1HDAC3 | |
| SCHEMBL3791109 | 0.83 | BCL9 (0.56) | MGLLBCL9CTNNB1MAPTSMN1; SMN2 | |
| SCHEMBL7079988 | 0.82 | BCL9 (0.73) | MGLLBCL9CTNNB1MAPTSMN1; SMN2 | |
| SCHEMBL530771 | 0.82 | BCL9 (0.73) | MGLLBCL9CTNNB1MAPTSMN1; SMN2 | |
| SCHEMBL570540 | 0.82 | BCL9 (0.73) | MGLLBCL9CTNNB1MAPTSMN1; SMN2 | |
| SCHEMBL531155 | 0.82 | BCL9 (0.73) | MGLLBCL9CTNNB1MAPTSMN1; SMN2 | |
| SCHEMBL3156654 | 0.81 | MGLL (0.56) | MGLLBCL9CTNNB1HDAC1HDAC3 | |
| SCHEMBL531007 | 0.81 | BCL9 (0.76) | MGLLBCL9CTNNB1MAPTSMN1; SMN2 | |
| SCHEMBL6200587 | 0.81 | MGLL (0.62) | MGLLBCL9CTNNB1HDAC1HDAC3 | |
| SCHEMBL9446512 | 0.80 | BCL9 (0.70) | MGLLBCL9CTNNB1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812051-B2 | Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential | ARQULE, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-20090226395-A1 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential | ARQULE, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2006020722-A2 | POLYMER CONJUGATES OF BETA-LAPACHONE AND BETA-LAPACHONE ANALOGS FOR TUMOR TARGETING | ARQULE, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060034796-A1 | conjugated to polyglutamic acid for enhanced permeability and retention effect | ARQULE, INC. | 2006-02-16 | — | — | US | disclosed |
| US-5547667-A | DRUG DELIVERY | FARMITALIA CARLO ERBA S.R.L. (IT) | 1996-08-20 | — | — | US | disclosed |
| EP-0495053-B1 | NEW LINKER FOR BIOACTIVE AGENTS | PHARMACIA SPA (IT) | 1996-03-27 | — | — | EP | disclosed |
| US-5387578-A | Releasing drugs from bioactive agents in order to improve the therapeutic efficacy and reduce their toxic effects | FARMITALIA CARLO ERBA S.R.L. (IT) | 1995-02-07 | — | — | US | disclosed |
| WO-1993023570-A1 | OLIGONUCLEOTIDES HAVING CONJUGATES ATTACHED AT THE 2'-POSITION OF THE SUGAR MOIETY | PHARMAGENICS, INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| EP-0495053-A1 | NEW LINKER FOR BIOACTIVE AGENTS. | ERBA CARLO SPA (IT) | 1992-07-22 | — | — | EP | disclosed |
| WO-1992002255-A1 | NEW LINKER FOR BIOACTIVE AGENTS | FARMITALIA CARLO ERBA S.R.L. (IT) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226395-A1 | Pharmaceutical compositions of beta-lapachone and beta-lapachone analogs with improved tumor targeting potential | NQO1, KEAP1, DLD | MGLL 4234/4885BCL9 3274/4885CTNNB1 706/4885 |
| US-20060034796-A1 | conjugated to polyglutamic acid for enhanced permeability and retention effect | QPCT, KEAP1, SLC46A1 | MGLL 4549/4885BCL9 3788/4885CTNNB1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.